A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)
Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Interventions

DRUG: BMS-986165

Sponsor

Bristol-Myers Squibb